Latest posts tagged with #INSEMA on Bluesky
🔍 #SABCS2025: #INSEMA Trial – #Radiotherapy Analysis (presented by Guido Hildebrandt)
Today’s presentation offered important insights into how radiotherapy was actually applied among patients undergoing breast-conserving surgery with or without sentinel lymph node biopsy #SLNB in the INSEMA trial.
#SABCS2025 Update: #INSEMA – Secondary results presented by Toralf Reimer
INSEMA Rando2 adds robust data on the oncological #safety of omitting cALND in patients with positive SLNB, under conditions of strict regional nodal irradiation #RNI and #radiotherapy quality assurance.
PinkOctober – Research Brings Hope: #INSEMA Study #GBG75
📖 Most recent results have been published in #NEJM: www.nejm.org/doi/full/10....
Exciting news: the latest INSEMA data will be presented as an Oral Presentation at the San Antonio Breast Cancer Symposium #SABCS2025 this December.
Photo of the speaker on the SABCS-podium.
Final primary results of the #INSEMA trial presented at #SABCS24: de-escalating surgical interventions for patients with early invasive #BreastCancer undergoing breast-conserving surgery.
Download the presentation: www.gbg.de/en/news/deta...
Read full @nejm.org paper: www.nejm.org/doi/full/10....
5. #INSEMA: 🚫 of axillary ✂️ for SLNBx w/ clinically N-ve invasive breast cancer staged T1/T2 (≤5 cm) scheduled to undergo breast-conserving surgery.
- 5yr iDFS 91.9% without ✂️ vs 91.7%
- Omission of surgical axillary staging was noninferior to SLNBx
6/6
#SABCS24 Day 3 Highlights #CommunityOnc:
1. #EUROPA: ET vs XRT HR+ ≥70 yrs
2. #PATINA: CDK4/6 HR+ HER2+ new SoC
3. #COMET: DCIS
4. #SUPREMO: XRT post mastectomy
5. #INSEMA: ALNBx
@sabcs.bsky.social @theaacr.bsky.social
@drsarahsammons.bsky.social
@erikahamilton9.bsky.social
Quick take from Dr Mridula George re the newly presented #INSEMA data (SLN sampling omission)- a med onc perspective @sabcs.bsky.social #SABCS @drgattimays.bsky.social
GS3 - #LessIsMore 👏 #INSEMA trial shows can OMIT nodal sampling in cN0 patients (preop Ax US) with G1/G2, ER+/HER2- tumors 2cm or less preop undergoing BCS and postop RT 🔑 Point - No difference in OS, iDFS @drgattimays.bsky.social @osuwexmed.bsky.social
